Technical Analysis for CIR - Circassia Pharmaceutical
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical CIR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | -0.20% | |
| Outside Day | Range Expansion | -0.20% | |
| Oversold Stochastic | Weakness | -0.20% | |
| Narrow Range Bar | Range Contraction | -3.53% | |
| Inside Day | Range Contraction | -3.53% | |
| Oversold Stochastic | Weakness | -1.60% | |
| Narrow Range Bar | Range Contraction | -3.53% | |
| NR7 | Range Contraction | -3.53% | |
| Oversold Stochastic | Weakness | -3.53% | |
| Volume Surge | Other | -3.15% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Fell Below Previous Day's Low | 1 day ago | |
| Down 2% | 1 day ago | |
| Down 1% | 1 day ago | |
| Rose Above Previous Day's High | 1 day ago | |
| Outside Day | 1 day ago |
Get a Trading Sidekick!
Circassia Pharmaceutical Description
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Target Pharmaceutical Medicine Pharmaceuticals Disease Testing Targeting Diseases Medical Specialties Therapy Oxide Smith Beta Biopharmaceutical Respirator Therapies Immunology Immune System Respiratory Disease Allergy Chronic Obstructive Pulmonary Disease Respiratory Diseases Immunotherapy Organ Systems Respiratory Therapy Glaxosmithkline Asthma Long Acting Beta Adrenoceptor Agonist
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|
| Indicator | Value |
|---|---|
| 52 Week High | 33.4025 |
| 52 Week Low | 0.255 |
| Average Volume | 981,142 |
| 200-Day Moving Average | 26.24 |
| 50-Day Moving Average | 27.12 |
| 20-Day Moving Average | 26.62 |
| 10-Day Moving Average | 25.37 |
| Average True Range | 1.42 |
| ADX | 16.8 |
| +DI | 15.18 |
| -DI | 16.70 |
| Chandelier Exit (Long, 3 ATRs ) | 25.75 |
| Chandelier Exit (Short, 3 ATRs ) | 28.30 |
| Upper Bollinger Band | 29.39 |
| Lower Bollinger Band | 23.84 |
| Percent B (%b) | 0.15 |
| BandWidth | 20.88 |
| MACD Line | -0.57 |
| MACD Signal Line | -0.35 |
| MACD Histogram | -0.2165 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.74 | ||||
| Resistance 3 (R3) | 26.96 | 26.48 | 26.39 | ||
| Resistance 2 (R2) | 26.48 | 25.95 | 26.37 | 26.28 | |
| Resistance 1 (R1) | 25.56 | 25.62 | 25.33 | 25.35 | 26.16 |
| Pivot Point | 25.09 | 25.09 | 24.97 | 24.98 | 25.09 |
| Support 1 (S1) | 24.17 | 24.55 | 23.93 | 23.95 | 23.14 |
| Support 2 (S2) | 23.69 | 24.22 | 23.58 | 23.02 | |
| Support 3 (S3) | 22.78 | 23.69 | 22.91 | ||
| Support 4 (S4) | 22.56 |
